Pharma Capital
Why invest in CYP?

Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions

Dr Ross Macdonald talked stemcell research with investors.
Dr Ross Macdonald, CEO, Cynata Therapeutics

Cynata Therapeutics' (ASX:CYP) CEO, Dr Ross Macdonald, joined Proactive's CEO Sessions in Sydney on Tuesday 14th March and Melbourne on Wednesday 15th March.

Cynata is now in a transition to a clinical stage company, with the focus on stem cells and regenerative medicine.

Earlier this year Cynata announced a breakthrough strategic partnership with Fujifilm which included the Japanese company investing in the company to become the largest shareholder.



Register here to be notified of future CYP Company articles
View full CYP profile

Cynata Therapeutics Timeline

View All

Related Articles

test tubes in a laboratory
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.